Abstract:Abstract Motor inhibitory control, a core component of cognitive control, is impaired in Parkinson’s disease, dramatically impacting patients’ abilities to implement goal-oriented adaptive strategies. A progressive loss of the midbrain’s dopamine neurons characterizes Parkinson’s disease and causes motor features responsive to dopaminergic treatments. Although such treatments restore motor symptoms, their impact on response inhibition is controversial. Most studies failed to show any effect of dopaminergic medicaments, although three studies found that these drugs selectively improved inhibitory control in early-stage patients. Importantly, all previous studies assessed only one domain of motor inhibition, i.e. reactive inhibition (the ability to react to a stop signal). The other domain, i.e. proactive inhibition (the ability to modulate reactive inhibition pre-emptively according to the current context), was utterly neglected. To re-examine this issue, we recruited cognitively unimpaired Parkinson’s patients under dopaminergic treatment in the early (Hoehn and Yahr, 1–1.5, n = 20), intermediate (Hoehn and Yahr 2, n = 20), and moderate/advanced (Hoehn and Yahr, 2.5–3, n = 20) stages of the disease. Using a cross-sectional study design, we compared their performance on a simple reaction-time task and a stop-signal task randomly performed twice on dopaminergic medication (ON) and after medication withdrawal (OFF). Normative data were collected on 30 healthy controls. Results suggest that medication effects are stage-dependent. In Hoehn and Yahr 1–1.5 patients, drugs selectively impair reactive inhibition, leaving proactive inhibition unaffected. In the ON state, Hoehn and Yahr two patients experienced impaired proactive inhibition, whereas reactive inhibition is no longer affected, as it deteriorates even during the OFF state. By contrast, Hoehn and Yahr 2.5–3 patients exhibited less efficient reactive and proactive inhibition in the OFF state, and medication slightly improved proactive inhibition. This evidence aligns with the dopamine overdose hypothesis, indicating that drug administration may overdose intact dopamine circuitry in the earliest stages, impairing associated cognitive functions. In later stages, the progressive degeneration of dopaminergic neurons prevents the overdose and can exert some beneficial effects. Thus, our findings suggest that inhibitory control assessment might help tailor pharmacological therapy across the disease stage to enhance Parkinson’s disease patients’ quality of life by minimizing the hampering of inhibitory control and maximizing the reduction of motor symptoms.

Dopaminergic therapy disrupts decision‐making in impulsive‐compulsive Parkinsonian patients

Risk Factors of Impulsive-Compulsive Behaviors in PD Patients: a Meta-Analysis

Advances in magnetic resonance imaging of impulsive-compulsive behavior in Parkinson′s disease

Subjective feelings associated with expectations and rewards during risky decision-making in impulse control disorder

Deepening the decisional processes under value-based conditions in patients affected by Parkinson's disease: A comparative study

Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management

Impulse control disorders in Parkinson's disease are associated with dysfunction in stimulus valuation but not action valuation

New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease

Iowa Gambling Task Impairment in Parkinson's Disease Can Be Normalised by Reduction of Dopaminergic Medication after Subthalamic Stimulation

L-Dopa Medication Remediates Cognitive Inflexibility, but Increases Impulsivity in Patients with Parkinson’s Disease

Characteristics of behavioural addiction in Parkinson's disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case-control study

Human moral decision-making through the lens of Parkinson’s disease

In Parkinson's disease dopaminergic medication and deep brain stimulation of the subthalamic nucleus increase motor, but not reflection and cognitive impulsivity

Inhibition of Indirect Pathway Activity Causes Abnormal Decision-Making In a Mouse Model of Impulse Control Disorder in Parkinson's Disease

Effects of dopaminergic treatment on inhibitory control differ across Hoehn and Yahr stages of Parkinson’s disease

Brain structural and functional signatures of impulsive–compulsive behaviours in Parkinson’s disease

Clinical management model for impulse control disorders in Parkinson's disease

Parkinson's disease and dopaminergic therapy—differential effects on movement, reward and cognition

Impulse control disorder: Review on clinical, pharmacologic, and genetic risk factors

Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism

Impaired corticostriatal connectivity in impulse control disorders in Parkinson disease